Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-01-30

AUTHORS

Grégoire Robert, Aurélien Descazeaud, Gilles Karsenty, Christian Saussine, Abdel-Rahmène Azzouzi, Alexandre de la Taille, François Desgrandchamps, Antoine Faix, Marc Fourmarier, Aurore Georget, Antoine Benard, Nicolas Barry Delongchamps

ABSTRACT

ObjectiveTo explore efficacy and safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperperplasia.Materials and methodsA phase 3 multicenter open-labeled study randomised patients to receive BoNT-A prostatic injection or optimized medical therapy. BoNT-A injection consisted in trans-rectal injections of 200 UI in the transitional zone of the prostate. Optimal medical therapy consisted in oral medication with any drug patented for LUTS. One month (M1) after randomisation patients in the BoNT-A group were asked to stop any medical therapy related to LUTS. The main judgment criterion was the IPSS score at M4. Per-protocol analysis was performed with a non-inferiority hypothesis (ΔIPSS < 3).Results127 patients were randomised to BoNT-A (n = 64) or medical therapy (n = 63). At randomisation mean IPSS was 16.9 ± 7.2 in the BoNT-A group vs 15.7 ± 7.3 in control. In the BoNT-A group, 44 patients (73.3%) could interrupt medical therapy for LUTS from M1 to M4. At M4, mean IPSS score was 12.0 ± 6.7 in the BoNT-A group vs 11.8 ± 6.9 in control. After adjustment for baseline IPSS, delta IPSS between groups was 0.01; 95% CI [− 2.14; 2.11] leading to accept the non-inferiority hypothesis.ConclusionsFour months after BoNT-A injection, most of the patients could interrupt LUTS-related medical treatments. In these patients, IPSS improvement was not inferior to optimized medical treatment, but the study design did not allow to conclude that this improvement was related with study drug rather than with sustained placebo effect.Trial registrationNCT01275521 More... »

PAGES

921-929

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-018-2193-y

DOI

http://dx.doi.org/10.1007/s00345-018-2193-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100717761

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29383480


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Botulinum Toxins, Type A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intralesional", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lower Urinary Tract Symptoms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuromuscular Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Hyperplasia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Withholding Treatment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU de Bordeaux, Bordeaux Pellegrin University Hospital, Universit\u00e9 de Bordeaux, Place Am\u00e9lie Raba L\u00e9on, 33000, Bordeaux, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU de Bordeaux, Bordeaux Pellegrin University Hospital, Universit\u00e9 de Bordeaux, Place Am\u00e9lie Raba L\u00e9on, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robert", 
        "givenName": "Gr\u00e9goire", 
        "id": "sg:person.01072153454.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072153454.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU de Limoges, 87042, Limoges, France", 
          "id": "http://www.grid.ac/institutes/grid.411178.a", 
          "name": [
            "Department of Urology, CHU de Limoges, 87042, Limoges, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Descazeaud", 
        "givenName": "Aur\u00e9lien", 
        "id": "sg:person.01066705041.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066705041.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU de Marseille, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.414336.7", 
          "name": [
            "Department of Urology, CHU de Marseille, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karsenty", 
        "givenName": "Gilles", 
        "id": "sg:person.016322473621.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016322473621.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU de Strasbourg, Strasbourg, France", 
          "id": "http://www.grid.ac/institutes/grid.412220.7", 
          "name": [
            "Department of Urology, CHU de Strasbourg, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saussine", 
        "givenName": "Christian", 
        "id": "sg:person.0675466517.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675466517.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU d\u2019Angers, Angers, France", 
          "id": "http://www.grid.ac/institutes/grid.411147.6", 
          "name": [
            "Department of Urology, CHU d\u2019Angers, Angers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Azzouzi", 
        "givenName": "Abdel-Rahm\u00e8ne", 
        "id": "sg:person.0640033232.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640033232.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU Henri Mondor, APHP, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.411388.7", 
          "name": [
            "Department of Urology, CHU Henri Mondor, APHP, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de la Taille", 
        "givenName": "Alexandre", 
        "id": "sg:person.01264427360.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264427360.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, H\u00f4pital Saint-Louis, APHP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "Department of Urology, H\u00f4pital Saint-Louis, APHP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desgrandchamps", 
        "givenName": "Fran\u00e7ois", 
        "id": "sg:person.01324441427.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324441427.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Clinique Beausoleil, Montpellier, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, Clinique Beausoleil, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faix", 
        "givenName": "Antoine", 
        "id": "sg:person.0673732516.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673732516.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CH du Pays d\u2019Aix, Aix en Provence, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CH du Pays d\u2019Aix, Aix en Provence, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fourmarier", 
        "givenName": "Marc", 
        "id": "sg:person.01140665007.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140665007.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CHU de Bordeaux, Clinical Epidemiology Unit, P\u00f4le de Sant\u00e9 Publique, 33000, Bordeaux, France", 
          "id": "http://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "CHU de Bordeaux, Clinical Epidemiology Unit, P\u00f4le de Sant\u00e9 Publique, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Georget", 
        "givenName": "Aurore", 
        "id": "sg:person.0712347162.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712347162.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CHU de Bordeaux, Clinical Epidemiology Unit, P\u00f4le de Sant\u00e9 Publique, 33000, Bordeaux, France", 
          "id": "http://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "CHU de Bordeaux, Clinical Epidemiology Unit, P\u00f4le de Sant\u00e9 Publique, 33000, Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benard", 
        "givenName": "Antoine", 
        "id": "sg:person.01346320132.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346320132.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, H\u00f4pital Cochin, APHP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Department of Urology, H\u00f4pital Cochin, APHP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barry Delongchamps", 
        "givenName": "Nicolas", 
        "id": "sg:person.01060107335.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060107335.30"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-01-30", 
    "datePublishedReg": "2018-01-30", 
    "description": "ObjectiveTo explore efficacy and  safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperperplasia.Materials and methodsA phase 3 multicenter open-labeled study randomised patients to receive BoNT-A prostatic injection or optimized medical therapy. BoNT-A injection consisted in trans-rectal injections of 200 UI in the transitional zone of the prostate. Optimal medical therapy consisted in oral medication with any drug patented for LUTS. One month (M1) after randomisation patients in the BoNT-A group were asked to stop any medical therapy related to LUTS. The main judgment criterion was the IPSS score at M4. Per-protocol analysis was performed with a non-inferiority hypothesis (\u0394IPSS\u00a0<\u00a03).Results127 patients were randomised to BoNT-A (n\u00a0=\u00a064) or medical therapy (n\u00a0=\u00a063). At randomisation mean IPSS was 16.9\u00a0\u00b1\u00a07.2 in the BoNT-A group vs 15.7\u00a0\u00b1\u00a07.3 in control. In the BoNT-A group, 44 patients (73.3%) could interrupt medical therapy for LUTS from M1 to M4. At M4, mean IPSS score was 12.0\u00a0\u00b1\u00a06.7 in the BoNT-A group vs 11.8\u00a0\u00b1\u00a06.9 in control. After adjustment for baseline IPSS, delta IPSS between groups was 0.01; 95% CI [\u2212\u00a02.14; 2.11] leading to accept the non-inferiority hypothesis.ConclusionsFour months after BoNT-A injection, most of the patients could interrupt LUTS-related medical treatments. In these patients, IPSS improvement was not inferior to optimized medical treatment, but the study design did not allow to conclude that this improvement was related with study drug rather than with sustained placebo effect.Trial registrationNCT01275521", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00345-018-2193-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "lower urinary tract symptoms", 
      "urinary tract symptoms", 
      "medical therapy", 
      "prostatic injection", 
      "non-inferiority hypothesis", 
      "tract symptoms", 
      "IPSS score", 
      "medical treatment", 
      "multicenter open-label study", 
      "open-label study", 
      "optimal medical therapy", 
      "main judgment criterion", 
      "randomized clinical trials", 
      "benign prostatic hyperplasia", 
      "IPSS improvement", 
      "study drug", 
      "oral medications", 
      "baseline IPSS", 
      "prostatic hyperplasia", 
      "botulinum toxin", 
      "clinical trials", 
      "placebo effect", 
      "patients", 
      "therapy", 
      "IPSS", 
      "study design", 
      "BoNT", 
      "injection", 
      "protocol analysis", 
      "symptoms", 
      "months", 
      "drugs", 
      "treatment", 
      "group", 
      "scores", 
      "medications", 
      "M4", 
      "hyperplasia", 
      "randomisation", 
      "prostate", 
      "ObjectiveTo", 
      "trials", 
      "efficacy", 
      "control", 
      "transitional zone", 
      "toxin", 
      "safety", 
      "hypothesis", 
      "improvement", 
      "M1", 
      "adjustment", 
      "management", 
      "criteria", 
      "study", 
      "effect", 
      "judgment criteria", 
      "cis", 
      "results", 
      "analysis", 
      "UI", 
      "materials", 
      "design", 
      "zone", 
      "Botulinum Neurotoxin Type A (BoNT-A) prostatic injection", 
      "Neurotoxin Type A (BoNT-A) prostatic injection", 
      "Type A (BoNT-A) prostatic injection", 
      "A (BoNT-A) prostatic injection", 
      "benign prostatic hyperperplasia", 
      "prostatic hyperperplasia", 
      "hyperperplasia", 
      "methodsA phase 3 multicenter open-labeled study", 
      "phase 3 multicenter open-labeled study", 
      "trans-rectal injections", 
      "randomisation patients", 
      "Results127 patients", 
      "delta IPSS", 
      "ConclusionsFour months", 
      "sustained placebo effect", 
      "Trial registrationNCT01275521 Prostatic injection", 
      "registrationNCT01275521 Prostatic injection"
    ], 
    "name": "Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial", 
    "pagination": "921-929", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100717761"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-018-2193-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29383480"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-018-2193-y", 
      "https://app.dimensions.ai/details/publication/pub.1100717761"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_785.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00345-018-2193-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2193-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2193-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2193-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2193-y'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      21 PREDICATES      119 URIs      111 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-018-2193-y schema:about N04bdd613cfb94979ababcc8e0e4a0155
2 N0978e299f9eb40629dabf177754f3755
3 N0a5fd3778bed4f0697f53162067b92cd
4 N0ecb702319054af882146c22a61965d5
5 N33bb839b96144a7ba509aa84ee0f355e
6 N3596b9b7bf39405683d3daef816d0357
7 N495dd42b49994ba0a183ca11d7b14223
8 N583337adbc934d92980244055ce10595
9 N7f245fb19c5449709c8a566f6526f4ec
10 Nccd863f32dcc49ad8cdb4b28ab0aa56f
11 Nd2c8fe4032994f52b32f0e3605420935
12 Nd9bb962c84bc40a38d3ca385cca42194
13 Ne6b97e6339aa4badbd26d0fa7b73641a
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N1a9ceb5c270a43f3bc111bf4f91593c8
17 schema:datePublished 2018-01-30
18 schema:datePublishedReg 2018-01-30
19 schema:description ObjectiveTo explore efficacy and safety of Botulinum Neurotoxin Type A (BoNT-A) prostatic injection in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperperplasia.Materials and methodsA phase 3 multicenter open-labeled study randomised patients to receive BoNT-A prostatic injection or optimized medical therapy. BoNT-A injection consisted in trans-rectal injections of 200 UI in the transitional zone of the prostate. Optimal medical therapy consisted in oral medication with any drug patented for LUTS. One month (M1) after randomisation patients in the BoNT-A group were asked to stop any medical therapy related to LUTS. The main judgment criterion was the IPSS score at M4. Per-protocol analysis was performed with a non-inferiority hypothesis (ΔIPSS < 3).Results127 patients were randomised to BoNT-A (n = 64) or medical therapy (n = 63). At randomisation mean IPSS was 16.9 ± 7.2 in the BoNT-A group vs 15.7 ± 7.3 in control. In the BoNT-A group, 44 patients (73.3%) could interrupt medical therapy for LUTS from M1 to M4. At M4, mean IPSS score was 12.0 ± 6.7 in the BoNT-A group vs 11.8 ± 6.9 in control. After adjustment for baseline IPSS, delta IPSS between groups was 0.01; 95% CI [− 2.14; 2.11] leading to accept the non-inferiority hypothesis.ConclusionsFour months after BoNT-A injection, most of the patients could interrupt LUTS-related medical treatments. In these patients, IPSS improvement was not inferior to optimized medical treatment, but the study design did not allow to conclude that this improvement was related with study drug rather than with sustained placebo effect.Trial registrationNCT01275521
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf N2aa70f507eeb4126aad25b4b5e4adb98
24 Ncea369ecbf89448ab95f6d69df5d0f67
25 sg:journal.1094127
26 schema:keywords A (BoNT-A) prostatic injection
27 BoNT
28 Botulinum Neurotoxin Type A (BoNT-A) prostatic injection
29 ConclusionsFour months
30 IPSS
31 IPSS improvement
32 IPSS score
33 M1
34 M4
35 Neurotoxin Type A (BoNT-A) prostatic injection
36 ObjectiveTo
37 Results127 patients
38 Trial registrationNCT01275521 Prostatic injection
39 Type A (BoNT-A) prostatic injection
40 UI
41 adjustment
42 analysis
43 baseline IPSS
44 benign prostatic hyperperplasia
45 benign prostatic hyperplasia
46 botulinum toxin
47 cis
48 clinical trials
49 control
50 criteria
51 delta IPSS
52 design
53 drugs
54 effect
55 efficacy
56 group
57 hyperperplasia
58 hyperplasia
59 hypothesis
60 improvement
61 injection
62 judgment criteria
63 lower urinary tract symptoms
64 main judgment criterion
65 management
66 materials
67 medical therapy
68 medical treatment
69 medications
70 methodsA phase 3 multicenter open-labeled study
71 months
72 multicenter open-label study
73 non-inferiority hypothesis
74 open-label study
75 optimal medical therapy
76 oral medications
77 patients
78 phase 3 multicenter open-labeled study
79 placebo effect
80 prostate
81 prostatic hyperperplasia
82 prostatic hyperplasia
83 prostatic injection
84 protocol analysis
85 randomisation
86 randomisation patients
87 randomized clinical trials
88 registrationNCT01275521 Prostatic injection
89 results
90 safety
91 scores
92 study
93 study design
94 study drug
95 sustained placebo effect
96 symptoms
97 therapy
98 toxin
99 tract symptoms
100 trans-rectal injections
101 transitional zone
102 treatment
103 trials
104 urinary tract symptoms
105 zone
106 schema:name Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial
107 schema:pagination 921-929
108 schema:productId N548bdca32e094eafa87d1cd41b72f992
109 Na181604e02a848e0b06a08be966e65b6
110 Nde39c4d5d71144048faf6bd46ff0dd50
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100717761
112 https://doi.org/10.1007/s00345-018-2193-y
113 schema:sdDatePublished 2022-01-01T18:48
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Nda89b66642614504b09c747cc1bffe58
116 schema:url https://doi.org/10.1007/s00345-018-2193-y
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N04bdd613cfb94979ababcc8e0e4a0155 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Lower Urinary Tract Symptoms
122 rdf:type schema:DefinedTerm
123 N0978e299f9eb40629dabf177754f3755 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Botulinum Toxins, Type A
125 rdf:type schema:DefinedTerm
126 N0a5fd3778bed4f0697f53162067b92cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 N0ecb702319054af882146c22a61965d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Injections, Intralesional
131 rdf:type schema:DefinedTerm
132 N1a9ceb5c270a43f3bc111bf4f91593c8 rdf:first sg:person.01072153454.44
133 rdf:rest Nc9c4c24896a04a989d6728949dec60ac
134 N26cce63e24964904901878e39f4c7161 rdf:first sg:person.01324441427.88
135 rdf:rest N93baf4336ab143d8931b44ee8e480437
136 N292c863c9d6e4604b676981e5255281f rdf:first sg:person.016322473621.11
137 rdf:rest N4c3b26e4f1f446769381996161b76d0b
138 N2aa70f507eeb4126aad25b4b5e4adb98 schema:issueNumber 6
139 rdf:type schema:PublicationIssue
140 N2db71aeb7fb14e9b90c628d856ac34b0 rdf:first sg:person.01346320132.54
141 rdf:rest N57cefd181cb543b0a6676ccf16703aef
142 N33bb839b96144a7ba509aa84ee0f355e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name France
144 rdf:type schema:DefinedTerm
145 N3596b9b7bf39405683d3daef816d0357 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Neuromuscular Agents
147 rdf:type schema:DefinedTerm
148 N495dd42b49994ba0a183ca11d7b14223 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Aged
150 rdf:type schema:DefinedTerm
151 N4c3b26e4f1f446769381996161b76d0b rdf:first sg:person.0675466517.55
152 rdf:rest Nf87f5b0be3ca4a579efbff0407b2cfc9
153 N5064f4dd98bb4dea83b95d0dd91a8725 rdf:first sg:person.0712347162.83
154 rdf:rest N2db71aeb7fb14e9b90c628d856ac34b0
155 N548bdca32e094eafa87d1cd41b72f992 schema:name pubmed_id
156 schema:value 29383480
157 rdf:type schema:PropertyValue
158 N57cefd181cb543b0a6676ccf16703aef rdf:first sg:person.01060107335.30
159 rdf:rest rdf:nil
160 N583337adbc934d92980244055ce10595 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Prostatic Hyperplasia
162 rdf:type schema:DefinedTerm
163 N7f245fb19c5449709c8a566f6526f4ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Male
165 rdf:type schema:DefinedTerm
166 N7fc7ab68cbbb4e5f819bb55b7935c44c rdf:first sg:person.01264427360.56
167 rdf:rest N26cce63e24964904901878e39f4c7161
168 N86debd18b8074db69200745a1d6a3c46 rdf:first sg:person.01140665007.42
169 rdf:rest N5064f4dd98bb4dea83b95d0dd91a8725
170 N93baf4336ab143d8931b44ee8e480437 rdf:first sg:person.0673732516.64
171 rdf:rest N86debd18b8074db69200745a1d6a3c46
172 Na181604e02a848e0b06a08be966e65b6 schema:name dimensions_id
173 schema:value pub.1100717761
174 rdf:type schema:PropertyValue
175 Nc9c4c24896a04a989d6728949dec60ac rdf:first sg:person.01066705041.29
176 rdf:rest N292c863c9d6e4604b676981e5255281f
177 Nccd863f32dcc49ad8cdb4b28ab0aa56f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Aged, 80 and over
179 rdf:type schema:DefinedTerm
180 Ncea369ecbf89448ab95f6d69df5d0f67 schema:volumeNumber 36
181 rdf:type schema:PublicationVolume
182 Nd2c8fe4032994f52b32f0e3605420935 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Treatment Outcome
184 rdf:type schema:DefinedTerm
185 Nd9bb962c84bc40a38d3ca385cca42194 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Humans
187 rdf:type schema:DefinedTerm
188 Nda89b66642614504b09c747cc1bffe58 schema:name Springer Nature - SN SciGraph project
189 rdf:type schema:Organization
190 Nde39c4d5d71144048faf6bd46ff0dd50 schema:name doi
191 schema:value 10.1007/s00345-018-2193-y
192 rdf:type schema:PropertyValue
193 Ne6b97e6339aa4badbd26d0fa7b73641a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Withholding Treatment
195 rdf:type schema:DefinedTerm
196 Nf87f5b0be3ca4a579efbff0407b2cfc9 rdf:first sg:person.0640033232.58
197 rdf:rest N7fc7ab68cbbb4e5f819bb55b7935c44c
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
202 schema:name Clinical Sciences
203 rdf:type schema:DefinedTerm
204 sg:journal.1094127 schema:issn 0724-4983
205 1433-8726
206 schema:name World Journal of Urology
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01060107335.30 schema:affiliation grid-institutes:grid.411784.f
210 schema:familyName Barry Delongchamps
211 schema:givenName Nicolas
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060107335.30
213 rdf:type schema:Person
214 sg:person.01066705041.29 schema:affiliation grid-institutes:grid.411178.a
215 schema:familyName Descazeaud
216 schema:givenName Aurélien
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066705041.29
218 rdf:type schema:Person
219 sg:person.01072153454.44 schema:affiliation grid-institutes:None
220 schema:familyName Robert
221 schema:givenName Grégoire
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072153454.44
223 rdf:type schema:Person
224 sg:person.01140665007.42 schema:affiliation grid-institutes:None
225 schema:familyName Fourmarier
226 schema:givenName Marc
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140665007.42
228 rdf:type schema:Person
229 sg:person.01264427360.56 schema:affiliation grid-institutes:grid.411388.7
230 schema:familyName de la Taille
231 schema:givenName Alexandre
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264427360.56
233 rdf:type schema:Person
234 sg:person.01324441427.88 schema:affiliation grid-institutes:grid.413328.f
235 schema:familyName Desgrandchamps
236 schema:givenName François
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324441427.88
238 rdf:type schema:Person
239 sg:person.01346320132.54 schema:affiliation grid-institutes:grid.42399.35
240 schema:familyName Benard
241 schema:givenName Antoine
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346320132.54
243 rdf:type schema:Person
244 sg:person.016322473621.11 schema:affiliation grid-institutes:grid.414336.7
245 schema:familyName Karsenty
246 schema:givenName Gilles
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016322473621.11
248 rdf:type schema:Person
249 sg:person.0640033232.58 schema:affiliation grid-institutes:grid.411147.6
250 schema:familyName Azzouzi
251 schema:givenName Abdel-Rahmène
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640033232.58
253 rdf:type schema:Person
254 sg:person.0673732516.64 schema:affiliation grid-institutes:None
255 schema:familyName Faix
256 schema:givenName Antoine
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673732516.64
258 rdf:type schema:Person
259 sg:person.0675466517.55 schema:affiliation grid-institutes:grid.412220.7
260 schema:familyName Saussine
261 schema:givenName Christian
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675466517.55
263 rdf:type schema:Person
264 sg:person.0712347162.83 schema:affiliation grid-institutes:grid.42399.35
265 schema:familyName Georget
266 schema:givenName Aurore
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712347162.83
268 rdf:type schema:Person
269 grid-institutes:None schema:alternateName Department of Urology, CH du Pays d’Aix, Aix en Provence, France
270 Department of Urology, CHU de Bordeaux, Bordeaux Pellegrin University Hospital, Université de Bordeaux, Place Amélie Raba Léon, 33000, Bordeaux, France
271 Department of Urology, Clinique Beausoleil, Montpellier, France
272 schema:name Department of Urology, CH du Pays d’Aix, Aix en Provence, France
273 Department of Urology, CHU de Bordeaux, Bordeaux Pellegrin University Hospital, Université de Bordeaux, Place Amélie Raba Léon, 33000, Bordeaux, France
274 Department of Urology, Clinique Beausoleil, Montpellier, France
275 rdf:type schema:Organization
276 grid-institutes:grid.411147.6 schema:alternateName Department of Urology, CHU d’Angers, Angers, France
277 schema:name Department of Urology, CHU d’Angers, Angers, France
278 rdf:type schema:Organization
279 grid-institutes:grid.411178.a schema:alternateName Department of Urology, CHU de Limoges, 87042, Limoges, France
280 schema:name Department of Urology, CHU de Limoges, 87042, Limoges, France
281 rdf:type schema:Organization
282 grid-institutes:grid.411388.7 schema:alternateName Department of Urology, CHU Henri Mondor, APHP, Créteil, France
283 schema:name Department of Urology, CHU Henri Mondor, APHP, Créteil, France
284 rdf:type schema:Organization
285 grid-institutes:grid.411784.f schema:alternateName Department of Urology, Hôpital Cochin, APHP, Paris, France
286 schema:name Department of Urology, Hôpital Cochin, APHP, Paris, France
287 rdf:type schema:Organization
288 grid-institutes:grid.412220.7 schema:alternateName Department of Urology, CHU de Strasbourg, Strasbourg, France
289 schema:name Department of Urology, CHU de Strasbourg, Strasbourg, France
290 rdf:type schema:Organization
291 grid-institutes:grid.413328.f schema:alternateName Department of Urology, Hôpital Saint-Louis, APHP, Paris, France
292 schema:name Department of Urology, Hôpital Saint-Louis, APHP, Paris, France
293 rdf:type schema:Organization
294 grid-institutes:grid.414336.7 schema:alternateName Department of Urology, CHU de Marseille, Marseille, France
295 schema:name Department of Urology, CHU de Marseille, Marseille, France
296 rdf:type schema:Organization
297 grid-institutes:grid.42399.35 schema:alternateName CHU de Bordeaux, Clinical Epidemiology Unit, Pôle de Santé Publique, 33000, Bordeaux, France
298 schema:name CHU de Bordeaux, Clinical Epidemiology Unit, Pôle de Santé Publique, 33000, Bordeaux, France
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...